The FDA has issued a safety communication recommending that certain patients stop taking Allergan’s Viberzi, and for healthcare professionals to stop prescribing it to certain populations immediately.
Viberzi is supposed to help those with irritable bowel syndrome with diarrhea, or IBS-D, by decreasing bowel contractions, easing pain, and improving stool consistency.
Viberzi poses the most risk to individuals without a gallbladder. The FDA has received at least 120 ...
continue reading...May 27, 2015 was a busy day at the FDA and a good day for two competing pharmaceutical companies. Allergan’s Viberzi, as well as Valeant’s Xifaxan medications were both approved by the agency to treat IBS-D, or irritable bowel syndrome with diarrhea.
Patients suffering from irritable bowel syndrome must contend with frequent agonizing bouts of lower stomach distress. The pain can be intense and is amplified by ...
continue reading...
In an exchange with readers of the New England Journal of Medicine, researchers behind a recent Victoza study revealed that the drug may be linked to a higher risk of gall bladder problems.
Victoza is one of many injectable diabetes medications targeted in a multidistrict litigation in the U.S. District Court for the Southern District of California. Along with other insulin mimetics like Byetta, Januvia, and ...
continue reading...
